US20090004673A1 - Method for Determining Condition of Disseminated Intravascular Coagulation - Google Patents

Method for Determining Condition of Disseminated Intravascular Coagulation Download PDF

Info

Publication number
US20090004673A1
US20090004673A1 US12/162,879 US16287907A US2009004673A1 US 20090004673 A1 US20090004673 A1 US 20090004673A1 US 16287907 A US16287907 A US 16287907A US 2009004673 A1 US2009004673 A1 US 2009004673A1
Authority
US
United States
Prior art keywords
dic
adamts13
ttp
patient
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/162,879
Other languages
English (en)
Inventor
Tomoko Ono
Shinichiro Watanabe
Fumio Furusaki
Ko Igami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
LSI Medience Corp
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Mitsubishi Kagaku Iatron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken, Mitsubishi Kagaku Iatron Inc filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Assigned to JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE, MITSUBISHI KAGAKU IATRON, INC. reassignment JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FURUSAKI, FUMIO, IGAMI, KO, ONO, TOMOKO, WATANABE, SHINICHIRO
Publication of US20090004673A1 publication Critical patent/US20090004673A1/en
Assigned to MITSUBISHI CHEMICAL MEDIENCE CORPORATION reassignment MITSUBISHI CHEMICAL MEDIENCE CORPORATION MERGER (SEE DOCUMENT FOR DETAILS). Assignors: MITSUBISHI KAGAKU IATRON, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/106664—Blood serum or blood plasma standard or control

Definitions

  • the present invention relates to a method for determining a condition of disseminated intravascular coagulation (hereinafter referred to as DIC).
  • microthrombi are formed in microvasculature, in the presence of a severe underlying disease.
  • the microthrombi damage the microcirculation and cause organ dysfunction or a bleeding tendency.
  • the following three failures or reactions are observed in DIC:
  • the microthrombus formation causes a microcirculatory failure, and a variety of organs fall into dysfunction due to ischemia.
  • the microthrombus formation promotes a consumption coagulopathy, that is, an increase in tissue factor production on the surface of endothelial cells leads to activation of an extrinsic coagulation pathway. Further, coagulation factors and platelets are consumed, and a bleeding tendency occurs.
  • Hyperfibrinolysis that is, the fibrinolytic system activated due to the activation of coagulation, generates plasmin, which degrades fibrin.
  • the ⁇ -plasmin inhibitor ⁇ 2 PI
  • DIC is mainly characterized by the microthrombus formation caused by the abnormal and continuous activation of coagulation, but the fibrinolytic system is also activated.
  • the balance of coagulation and fibrinolysis varies in accordance with underlying diseases or cases. As such cases, a case in which coagulation is remarkably activated, but the fibrinolytic system is suppressed, and a case in which both the coagulation and fibrinolytic systems are remarkably activated, are known.
  • the former is designated coagulation-dominant DIC, and the latter is coagulation-suppressed DIC.
  • Coagulation-dominant DIC is often accompanied by infections, particularly sepsis, and organ failure is often observed as a clinical symptom in patients with coagulation-dominant DIC.
  • FDPs Fibrin degradation products
  • PIC Plasmin/plasmin inhibitor complex
  • DIC is an urgent disease requiring an early diagnosis and an early treatment.
  • Diagnosis of DIC is now carried out in accordance with the diagnostic criteria for DIC, established by the Ministry of Health and Welfare (Japan). In these diagnostic criteria, DIC is judged by scoring each value of 1) the presence or absence of organ failure, 2) the platelet count, 3) FDPs, 4) fibrinogen, and 5) the PT ratio (prothrombin time ratio).
  • the diagnostic criteria are suitable for a definitive diagnosis of DIC, but are not suitable for an early diagnosis of DIC. Where a clinical treatment of DIC is carried out in accordance with the diagnosis criteria, there are many cases in which DIC is at such an advanced stage that it is too late.
  • a decreased platelet count is caused by DIC.
  • conditions or diseases with such a decreased platelet count include, for example, a condition accompanied by myelosuppression (such as drugs, viral infections, blood diseases caused dyshemopoiesis, cirrhosis, hepatic insufficiency, thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS), and excess pleural effusion or ascites.
  • myelosuppression such as drugs, viral infections, blood diseases caused dyshemopoiesis, cirrhosis, hepatic insufficiency, thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS), and excess pleural effusion or ascites.
  • TTP thrombotic thrombocytopenic purpura
  • HUS hemolytic uremic syndrome
  • excess pleural effusion or ascites are sometimes accompanied by elevated FDPs and/or elevated D-
  • a treatment for DIC low-molecular-weight heparin or antithrombin III is administered, to suppress the multiple formations of thrombi in blood vessels and inhibit the progression of a consumption coagulopathy.
  • gabexate mesilate having an antithrombin activity and an antifibrinolytic effect is administered.
  • it is essential to replenish platelets by the administration of platelet concentrate.
  • fresh frozen plasma (FFP) is transfused.
  • a disease condition designated microangiopathic hemolytic anemia (MAHA) is observed in TTP, as well as DIC or HUS. If many microthrombi are formed in blood vessels due to a particular cause, many portions of the microcirculation become narrow. Erythrocytes which forcibly have passed through these narrowed portions are mechanically broken, and hemolysis occurs. These processes are considered the mechanism of the development of MAHA.
  • the main components of the microthrombi, which reduce the internal diameter of the vessels, are fibrin and platelets in DIC and TTP or HUS, respectively.
  • TTP was first reported in 1924 by Moschcowitz in the United State. TTP is a systemic severe disease which is caused by the clogging of arterioles with platelet aggregates (platelet thrombi), and characterized by the following symptoms: (1) thrombocytopenia (purpura is observed in the skin), (2) microangiopathic hemolytic anemia (caused by the breakdown of erythrocytes), (3) renal failures, (4) fever, and (5) neurologic disturbances.
  • thrombocytopenia purpura is observed in the skin
  • microangiopathic hemolytic anemia caused by the breakdown of erythrocytes
  • renal failures erythrocytes
  • (4) fever a cleaving protease specific to plasma vWF as a hemostatic factor
  • ADAMTS13 a cleaving protease specific to plasma vWF as a hemostatic factor
  • ADAMTS13 it is known that the amount of ADAMTS13 is significantly lowered in patients with TTP, in comparison with healthy persons (for example, non-patent reference 1, non-patent reference 2, or patent reference 1). If ADAMTS13 is deficient or reduced, unusually large vWF multimers (UL-vWFMs) released from vascular endothelial cells are not cleaved, and an excessive platelet aggregation occurs due to a high shear stress caused in the microcirculation or the like, and as a result, blood vessels are occluded with thrombi.
  • UL-vWFMs unusually large vWF multimers
  • patent reference 2 discloses a method of detecting thrombosis or the degree of thrombophilia, characterized by measuring ADAMTS13, and acute or chronic myeloid leukemia, acute promyelocytic leukemia, systemic lupus erythematosus, pulmonary embolism, cerebral infarction, veno-occlusive disease, acute lymphocytic leukemia, thrombotic microangiopathy, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, and deep vein thrombosis are used to exemplify thrombosis.
  • Patent reference 3 discloses a method of detecting platelet thrombosis or organ failure in a patient suffering from DIC or systemic inflammatory response syndrome (SIRS), comprising analyzing ADAMTS13 and/or a cleaving factor thereof (for example, elastase, plasmin, or thrombin).
  • SIRS systemic inflammatory response syndrome
  • atypical TTP having a slightly decreased or normal ADAMTS13 activity is known.
  • causes for atypical TTP were reported, and include congenital factors and acquired factors.
  • TTP is an extremely rare disease, which is generally caused by acquired factors, but rare cases caused by congenital factors are known as described below.
  • Clinical symptoms in TTP include, for example, diarrhea, abdominal pain, and blood stool due to ischemic enteritis, neurological symptoms such as convulsion and visual disorder, and renal disorder.
  • various changes accompanied by hemolysis are observed, for examples, peripheral blood erythrocytes broken by thrombus formation, anemia, decreased platelets, serum LDH (lactate dehydrogenase), elevated indirect bilirubin, or decreased haptoglobin. Elevated serum creatine is observed in patients with renal disorder.
  • FFP fresh frozen plasma
  • ADAMTS13 activity is remarkably decreased, and almost all the cases are positive for an autoantibody specific to ADAMTS13. Therefore, the administration of FFP alone is insufficient to treat acquired and idiopathic TTP, and a plasma exchange (PE) is the first option.
  • PE plasma exchange
  • a platelet transfusion before the PE is contraindicated.
  • the effects of PE are summarized as 1) the replenishment of ADAMTS13, 2) the removal of an ADAMTS13 inhibitor, 3) the removal of UL-vWFM, and 4) the replenishment of normal vWF necessary for hemostasis.
  • an immunosuppressant such as vincristine or endoxan, or splenectomy should be considered for intractable cases or repetitive cases.
  • the mortality rate before the introduction of the PE or the FFP transfusion therapy was more than 80%, and the prognosis was very poor.
  • such an introduction or a combination thereof with an antiplatelet therapy has remarkably improved the prognosis, so that the survival rate becomes approximately 90% or more now.
  • many refractory cases and recurrent cases are known, and there remain problems to be solved.
  • advanced TTP is refractory and has a poor prognosis, and thus, an early diagnosis and an early treatment are necessary.
  • a platelet transfusion may be selected as a treatment for DIC, such a platelet transfusion is contraindicated in TTP, even if with remarkably decreased platelets, because the platelet transfusion will aggravate the condition, as described above. Therefore, decreased platelets are observed in both DIC and TTP, but it is desired in the clinical field to clearly distinguish them from each other, so as to carry out an appropriate diagnosis and an appropriate treatment.
  • the present inventors have conducted intensive studies, and found that a group of patients diagnosed with DIC included a subgroup of patients possibly with acquired TTP, by classifying the patients with DIC according to either the amount (concentration) of ADAMTS13 or enzyme activity of ADAMTS13, or the combination thereof, preferably a combination of the amount (concentration) of ADAMTS13 and/or enzyme activity of ADAMTS13 and the amount (concentration) of vWF.
  • the present inventors differentiated “DIC to be diagnosed as TTP” from “DIC irrelevant to TTP”, which could not be differentiated from each other based on clinical findings and known markers, and found that each group of such patients can be treated with a therapy specific to each disease so as to improve the prognosis, and the present invention was completed.
  • An object of the present invention is to provide a method and kit for differentiating between a patient with TTP and a patient with DIC, which could not be distinguished from each other based on clinical findings and known markers.
  • the object can be solved by the present invention, that is, a method for determining a condition of disseminated intravascular coagulation, characterized by analyzing the amount (concentration) and/or enzyme activity of a von Willebrand factor-cleaving protease (ADAMTS13) in a patient suffering from disseminated intravascular coagulation.
  • ADAMTS13 von Willebrand factor-cleaving protease
  • the amount (concentration) of a von Willebrand factor (vWF) is further analyzed.
  • the von Willebrand factor-cleaving protease is immunologically analyzed.
  • the present invention relates to a kit for determining a condition of disseminated intravascular coagulation, comprising an antibody or a fragment thereof which specifically binds to a von Willebrand factor-cleaving protease.
  • analysis includes a detection to determine a presence or absence of a substance (for example, ADAMTS13 or vWF) to be analyzed, and a measurement to quantitatively or semi-quantitatively determine the amount (concentration) or activity of a substance to be analyzed.
  • a substance for example, ADAMTS13 or vWF
  • DIC and TTP are similar in their conditions, and thus, are difficult to accurately diagnose. Further, in both cases, if an appropriate treatment determined by an early diagnosis is not carried out at an early stage, the patient will die, and therefore, it is very important to differentiate “DIC to be diagnosed as TTP” from “DIC irrelevant to TTP”. According to the present invention, in patients diagnosed with DIC based on the present diagnosis criteria, “DIC to be diagnosed as TTP” can be differentiated from “DIC irrelevant to TTP”, and an appropriate treatment can be carried out to elevate the survival rate or reduce the mortality rate.
  • FIG. 1 is a graph showing the result of measuring amounts of the ADAMTS13 antigen (Aag).
  • FIG. 2 is a graph showing the result of measuring enzyme activities of ADAMTS13 (Aact).
  • FIG. 3 is a graph showing the result of measuring amounts of the vWF antigen (Vag).
  • FIG. 4 is a graph showing Vag/Aag.
  • FIG. 5 is a graph showing Vag/Aact.
  • the condition of DIC can be determined by analyzing at least one (preferably both) of the amount (concentration) of ADAMTS13 and/or the enzyme activity of ADAMTS13, or using a combination of the amount (concentration) of vWF and at least one (preferably both) of the amount (concentration) of ADAMTS13 and/or the enzyme activity of ADAMTS13, in a patient with DIC.
  • the term “to determine a condition of DIC” as used herein includes to determine various conditions in a patient suffering from DIC, which are useful for the decision of an appropriate treatment, for example, to select patients to be accurately diagnosed with TTP, and to be treated with another therapy, from among patients diagnosed with DIC, that is, to differentiate between “DIC to be diagnosed as TTP” and “DIC irrelevant to TTP”. Further, the term “to determine a condition of DIC” as used herein further include a decision and a prediction on the basis of the determination of the conditions, for example, a determination of an appropriate treatment, a prognosis, and a monitoring.
  • a differential diagnosis between “DIC possible to be TTP” and “DIC irrelevant to TTP” can be carried out by using, as an index, for example, the difference in the amount (concentration) and/or enzyme activity of ADAMTS13 in a patient with DIC.
  • the DIC patient group can be categorized, by using as an index a combination of the amount (concentration) and/or enzyme activity of ADAMTS13 and the amount (concentration) of vWF [for example, a ratio of the amount of vWF to the amount (concentration) and/or enzyme activity of ADAMTS13], into, for example, three subgroups to differentiate “DIC to be diagnosed as TTP” from “DIC irrelevant to TTP”, and thus, an appropriate therapy specific to each patient can be proposed.
  • thresholds of the amount (concentration) of ADAMTS13 and ADAMTS13 activity may be selected.
  • vWF-cleaving protease means a metalloprotease, sometimes referred to as ADAMTS13, which specifically cleaves the von Willebrand factor (VWF) at the bond between tyrosine (842) and methionine (843) contained in an A2 domain thereof.
  • ADAMTS13 is significantly decreased in patients with TTP in comparison of healthy persons [for example, Zheng X. et al., J. Biol. Chem., (U.S.A.), 2001, vol. 276, p. 41059-41063; Furlan M. et al., Blood, (U.S.A.), 1997, vol. 89, p. 3097-3103; and WO 00/50904].
  • ADAMTS13 was significantly decreased in DIC patients with a variety of underlying diseases but diagnosed based on the DIC score, in comparison with healthy persons, and that amounts of ADAMTS13 in a group of patients diagnosed with TTP were 5% to 45%, and amounts of ADAMTS13 in a group of DIC patients ranged from 10% to 95% [Ono T. et al., The Japanese Society on Thrombosis and Hemostasis, 2004 (Abstracts were published on October 1.)].
  • a subject (a person to be diagnosed) to whom the method of the present invention may be applied is a DIC patient.
  • a preferred sample to be assayed is, for example, blood such as plasma or a serum.
  • samples other than blood include various body fluids, such as cell or tissue fluids, lymph, a thymic fluid, an ascites fluid, an amniotic fluid, gastric juices, urine, pancreatic juices, spinal fluid, and saliva.
  • the plasma is preferably citrated plasma or heparinized plasma.
  • a determination of a condition of DIC and a decision of appropriate therapy can be carried out by collecting samples from DIC patients and TTP patients, measuring the concentration of ADAMTS13, ADAMTS13 activity, and/or the concentration of vWF, and comparing the measured values.
  • various thresholds for judgment such as thresholds for the concentration of ADAMTS13 and ADAMTS13 activity, and a threshold for a ratio of vWF to concentration or activity of ADAMTS13, by using samples collected from TTP patients.
  • categorization can be, for example, carried out.
  • the amount (hereinafter referred to as Aag) of ADAMTS13 is, for example, 30% or less. 2)
  • the activity (hereinafter referred to as Aact) of ADAMTS13 is, for example, 15% or less.
  • the ratio (Aact/Aag) of the amount of ADAMTS13 to the ADAMTS13 activity, for example, is 2.0 or more.
  • patient groups may be further categorized, on the basis of a ratio (Vag/Aag) of the amount of vWF (hereinafter referred to as Vag) to the amount of ADAMTS13 (Aag) and a ratio (Vag/Aact) of the amount of vWF to the ADAMTS13 activity (Aact), into the following three groups: Group 1: Vag/Aag is, for example, 8 or more, and Vag/Aact is, for example, 16 or more. Group 2: Vag/Aag is, for example, 8 or less, and Vag/Aact is, for example, 16 or more. Group 3: Other than groups 1 and 2 (i.e., Vag/Aact is, for example, less than 16.)
  • Group 1 and Group 2 are a “group of DIC patients to be diagnosed with TTP”, and Group 3 is a “group of DIC patients irrelevant to TTP”.
  • Aag, Aact, and Vag are relative values to normal values, and the above ratios (Aact/Aag, Vag/Aag, and Vag/Aact) are calculated from these relative values.
  • thresholds for judgment have previously been determined, measured values obtained from a subject whose condition is to be predicted are used to analyze Aag and/or Aact, or Aag and/or Aact and Vag (such as Vag/Aag and/or Vag/Aact), and then, the above judgment and/or prediction can be carried out for the subject.
  • the thresholds for judgment are considered to depend on various conditions, such as an underlying disease, sex, or age. However, those skilled in the art can easily determine the normal ranges or the thresholds for judgment, by selecting an appropriate statistical population corresponding to the subject(s) and statistically processing data obtained from that population.
  • a method of analyzing the concentration of ADAMTS13 is not limited, so long as an amount of ADAMTS13 may be quantitatively or semi-quantitatively determined, or a presence or absence of ADAMTS13 may be judged, by the analyzing method.
  • Examples of the analyzing method include an immunological method using an anti-ADAMTS13 antibody or a fragment thereof (such as an enzyme-linked immunosorbent assay, a latex agglutination assay, a chemiluminescence immunoassay, a fluorescent antibody method, a radioimmunoassay, immunoprecipitation, immunohistochemical staining, or Western blotting), a biochemical method (such as an enzyme assay), and a molecular biological method for measuring an mRNA.
  • an immunological method using an anti-ADAMTS13 antibody or a fragment thereof such as an enzyme-linked immunosorbent assay, a latex agglutination assay, a chemiluminescence immunoassay, a fluorescent antibody method, a radioimmunoassay, immunoprecipitation, immunohistochemical staining, or Western blotting
  • a biochemical method such as an enzyme assay
  • an anti-ADAMTS13 antibody may be prepared in accordance with a known method, such as a method described in WO 2004/029242.
  • Each immunoassay may be carried out in accordance with, for example, WO 2004/029242.
  • the immunological method means a method of analyzing ADAMTS13 by an ELISA method, a latex method, or immunochromatography, using an antibody against ADAMTS13.
  • the immunological method there may be mentioned, for example, a competition method using a labeled ADAMTS13, a sandwich method using a labeled antibody, a latex bead method in which an agglutination of beads coated with an antibody is observed, and a method using an antibody conjugated to a colored particle such as gold colloid. Any method using the antibody against ADAMTS13 is included in preferred embodiments of the present invention.
  • the antibody may be monoclonal or polyclonal.
  • An antibody fragment, such as Fab, Fab′, F(ab′) 2 , or Fv may be used.
  • the enzyme activity of ADAMTS13 may be measured by, for example, a method utilizing an SDS-agarose electrophoresis [Furlan M. et al., Blood, (U.S.A.), 1997, vol. 89, p. 3097-3103]; an ELISA method using a recombinant antigen of the A2 domain of vWF, as a substrate of vWF [Whitelock J L et al., Journal of Thrombosis and Haemostasis, (United Kingdom), 2004, vol. 2, p.
  • a quenched fluorescent substrate FRETS-VWF73 prepared by introducing a fluorescent group [2-(N-methylamino)benzoyl, Nma] and a quenching group (2,4-dinitrophenyl, Dnp) into a synthetic peptide corresponding to 73 residues of ASP1596-Argl668 located in the A2 domain of vWF, as a substrate of the vWF cleaving protease [Kokame K. et al, British Journal of Haematology, (United Kingdom), 2005, vol. 129, p. 93-100]. Further, a method described in the specification of Japanese Patent Application No.
  • an analyzing method comprising the steps of (1) in a liquid, bringing a sample possibly containing ADAMTS13 into contact with an immobilized substrate prepared by binding vWF or a fragment thereof to an insoluble carrier, (2) separating the liquid from the insoluble carrier, and (3) analyzing the vWF or the fragment thereof which remains in the insoluble carrier, and/or a vWF fragment which is released from the insoluble carrier and is contained in the liquid, may be used.
  • the concentration of vWF may be measured by, for example, a method of measuring an activity by utilizing an aggregation activity of human platelets and a ristocetin cofactor [Allain J P et al., J. Lab. Clin. Med., (U.S.A.), 1975, vol. 85, p. 318-328]; or an immunoassay using an anti-vWF antibody [Brown J E et al., Thromb. Res., (U.S.A.), 1986, vol. 43, p. 303-311].
  • the immunoassay is preferable from the viewpoint of sensitivity and convenience.
  • the kit of the present invention comprises at least an anti-ADAMTS13 antibody or a fragment thereof. It is preferable that the kit of the present invention comprises two or more types of anti-ADAMTS13 antibodies.
  • the anti-ADAMTS13 antibody may be a monoclonal antibody or a polyclonal antibody. When two or more types of anti-ADAMTS13 antibodies are contained, one of the antibodies may be labeled as a second antibody, or a labeled anti-second-antibody antibody may be further added to the kit.
  • PAI-1 means a plasminogen activator inhibitor-1
  • D-D means D-dimer
  • Fbg fibrinogen
  • FDP-P means plasma FDPs
  • PLT means platelets
  • TAT means a thrombin/antithrombin III complex.
  • the patients diagnosed with DIC included patients with a remarkably decreased platelet count, but these patients could not be distinguished from patients with TTP, based on only conventional coagulation and fibrinolysis marker levels.
  • ADAMTS13 antigen was determined using a commercially available kit (ADAMTS-13 ELISA kit; Mitsubishi Kagaku Iatron).
  • the enzyme activity (Aact) of ADAMTS13 was determined by an SDS-agarose gel electrophoresis [Furlan M. et al., Blood, (U.S.A.), 1997, vol. 89, p. 3097-3103].
  • the amount (Vag) of a vWF antigen was determined using a commercially available kit (STA LIAtest: Roche Diagnostics).
  • the measured values obtained from the DIC patients were categorized in accordance with the following indications, based on the measured values obtained from the TTP patients.
  • patients in which two or three items from among the following items 1) to 3) apply were categorized into a “group of DIC patients who possibly to suffer from TTP (group A)”, and the others were categorized into a “group of DIC patients who do not possibly to suffer from TTP (group B)”.
  • the amount (Aag) of the ADAMTS13 antigen is 30% or less. 2) The enzyme activity (Aact) of ADAMTS13 is 15% or less. 3) The ratio (Aact/Aag) of the amount of ADAMTS13 to the ADAMTS13 activity is 2.0 or more.
  • patient groups group A and group B were further categorized into the following three groups: Group 1: Vag/Aag is 8 or more, and Vag/Aact is 16 or more. Group 2: Vag/Aag is 8 or less, and Vag/Aact is 16 or more. Group 3: Other than groups 1 and 2 (i.e., Vag/Aact is less than 16.)
  • Each patient group was compared with healthy persons, to obtain the results as shown in FIG. 1 to FIG. 3 .
  • the results of the amount (Aag) of the ADAMTS13 antigen, the enzyme activity (Aact) of ADAMTS13, and the amount (Vag) of the vWF antigen apparent differences between the TTP group and the healthy person group were observed with respect with each marker. Further, the differences between the TTP group and Group 3 were observed with respect to the amount of the ADAMTS13 antigen and the enzyme activity of ADAMTS13, and both groups could be differentiated from each other.
  • Group 2 could be distinguished from the TTP group in the amount of the ADAMTS13 antigen, but could not be distinguished from the TTP group in the enzyme activity of ADAMTS13. With respect to the amount of the vWF antigen, no differences between the TTP group and the DIC groups (Group 1 to Group 3) were observed.
  • the TTP group and the DIC groups categorized into three subgroups were compared in Vag/Aag and Vag/Aact, to obtain the results shown in FIG. 4 and FIG. 5 , respectively.
  • the present invention can be applied to the use for an appropriate treatment of DIC.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US12/162,879 2006-01-31 2007-01-30 Method for Determining Condition of Disseminated Intravascular Coagulation Abandoned US20090004673A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006-023596 2006-01-31
JP2006023596 2006-01-31
PCT/JP2007/051489 WO2007088849A1 (ja) 2006-01-31 2007-01-30 播種性血管内凝固症候群の病態把握方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/051489 A-371-Of-International WO2007088849A1 (ja) 2006-01-31 2007-01-30 播種性血管内凝固症候群の病態把握方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/030,249 Division US8759018B2 (en) 2006-01-31 2011-02-18 Method for determining treatment of disseminated intravascular coagulation

Publications (1)

Publication Number Publication Date
US20090004673A1 true US20090004673A1 (en) 2009-01-01

Family

ID=38327421

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/162,879 Abandoned US20090004673A1 (en) 2006-01-31 2007-01-30 Method for Determining Condition of Disseminated Intravascular Coagulation
US13/030,249 Active 2028-06-05 US8759018B2 (en) 2006-01-31 2011-02-18 Method for determining treatment of disseminated intravascular coagulation

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/030,249 Active 2028-06-05 US8759018B2 (en) 2006-01-31 2011-02-18 Method for determining treatment of disseminated intravascular coagulation

Country Status (9)

Country Link
US (2) US20090004673A1 (ko)
EP (1) EP1988174B1 (ko)
JP (1) JP5060966B2 (ko)
KR (1) KR101367658B1 (ko)
CN (1) CN101374956B (ko)
AU (1) AU2007210643B2 (ko)
CA (1) CA2641189A1 (ko)
ES (1) ES2373989T3 (ko)
WO (1) WO2007088849A1 (ko)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9910052B2 (en) 2012-05-07 2018-03-06 Lsi Medience Corporation Method of diagnosing and treating infectious disseminated intravascular coagulation
US10209262B2 (en) * 2015-08-28 2019-02-19 Sysmex Corporation Blood sample analyzing method, blood sample analyzer, and system
US11567080B2 (en) 2016-01-08 2023-01-31 Kyoto University Diagnostic agent and medicine comprising ADAMTS13 as main ingredient

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101670103B1 (ko) * 2008-12-05 2016-10-27 박스알타 인코퍼레이티드 폰빌레브란트 인자의 ａｄａｍｔｓ１３－매개 생체내 절단을 측정하는 방법 및 그의 사용
SG11201400904SA (en) * 2011-09-30 2014-04-28 Somalogic Inc Cardiovascular risk event prediction and uses thereof
US10858689B2 (en) 2016-10-11 2020-12-08 Laboratory Corporation Of America Holdings Methods and systems for determining ADAMTS13 enzyme activity

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214346A1 (en) * 2003-04-22 2004-10-28 Friedrich Scheiflinger Diagnostic assay for anti-von willebrand factor cleaving protease ( ADAMTS13) antibodies
US20050186646A1 (en) * 2004-01-26 2005-08-25 Cruz Miguel A. Rapid assay to detect ADAMTS-13 activity
US20070275414A1 (en) * 2003-12-22 2007-11-29 Tomoko Ono Method of Detecting Thrombosis by Measuring Von Willenbrand Factor-Cleaving Protease
US20080096221A1 (en) * 2004-11-08 2008-04-24 Mitsubishi Kagaku Iatron, Inc. Method Of Detecting Platelet Thrombosis Or Organ Failure
US20090220990A1 (en) * 2006-02-16 2009-09-03 Mitsubishi Kagaku Iatron, Inc. Method and kit for detecting condition in patient with disturbance of consciousness

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050904A1 (de) 1999-02-25 2000-08-31 Baxter Aktiengesellschaft Testkit zur analytik der faktor-viii-spaltenden protease
JP2003505678A (ja) * 1999-07-23 2003-02-12 ザ スクリップス リサーチ インスティテュート 全血の凝固因子活性を測定する方法
EP1149906A1 (en) * 2000-04-25 2001-10-31 Pliva, Farmaceutska, Industrija, Dionicko Drustvo Thrombopoietin receptor modulating peptide
DE60124705T2 (de) * 2000-04-28 2007-09-13 Mitsubishi Kagaku Iatron, Inc. Automatische messpatrone und dazu gehoerendes messverfahren
CA2499926C (en) * 2002-09-25 2013-06-04 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Antibody against von willebrand factor cleaving enzyme and assay system using the same
EP1411134A1 (en) * 2002-10-15 2004-04-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Association of the H2 haplotype of the P2Y12 receptor with an increased risk for thrombosis and peripheral arterial disease
JP2005148793A (ja) 2003-11-11 2005-06-09 Seiko Epson Corp データ伝送における放射ノイズの低減
EP1568782A1 (de) * 2004-02-25 2005-08-31 Clemens Bockmeyer Diagnose und Therapie von ADAMTS-13 assoziierten Erkrankungen
JP4533995B2 (ja) * 2004-10-19 2010-09-01 アルフレッサファーマ株式会社 抗ａｄａｍｔｓ１３モノクローナル抗体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214346A1 (en) * 2003-04-22 2004-10-28 Friedrich Scheiflinger Diagnostic assay for anti-von willebrand factor cleaving protease ( ADAMTS13) antibodies
US20070275414A1 (en) * 2003-12-22 2007-11-29 Tomoko Ono Method of Detecting Thrombosis by Measuring Von Willenbrand Factor-Cleaving Protease
US20050186646A1 (en) * 2004-01-26 2005-08-25 Cruz Miguel A. Rapid assay to detect ADAMTS-13 activity
US20080096221A1 (en) * 2004-11-08 2008-04-24 Mitsubishi Kagaku Iatron, Inc. Method Of Detecting Platelet Thrombosis Or Organ Failure
US20090220990A1 (en) * 2006-02-16 2009-09-03 Mitsubishi Kagaku Iatron, Inc. Method and kit for detecting condition in patient with disturbance of consciousness

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9910052B2 (en) 2012-05-07 2018-03-06 Lsi Medience Corporation Method of diagnosing and treating infectious disseminated intravascular coagulation
US10209262B2 (en) * 2015-08-28 2019-02-19 Sysmex Corporation Blood sample analyzing method, blood sample analyzer, and system
US11567080B2 (en) 2016-01-08 2023-01-31 Kyoto University Diagnostic agent and medicine comprising ADAMTS13 as main ingredient

Also Published As

Publication number Publication date
JPWO2007088849A1 (ja) 2009-06-25
EP1988174A4 (en) 2009-06-03
CN101374956A (zh) 2009-02-25
JP5060966B2 (ja) 2012-10-31
AU2007210643A1 (en) 2007-08-09
US20110143369A1 (en) 2011-06-16
EP1988174B1 (en) 2011-10-12
AU2007210643B2 (en) 2013-09-19
KR20080091185A (ko) 2008-10-09
CN101374956B (zh) 2014-01-01
CA2641189A1 (en) 2007-08-09
ES2373989T3 (es) 2012-02-10
EP1988174A1 (en) 2008-11-05
WO2007088849A1 (ja) 2007-08-09
KR101367658B1 (ko) 2014-02-25
US8759018B2 (en) 2014-06-24

Similar Documents

Publication Publication Date Title
Yang et al. Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events
Hoek et al. Laboratory and clinical evaluation of an assay of thrombin-antithrombin III complexes in plasma.
US8759018B2 (en) Method for determining treatment of disseminated intravascular coagulation
Reddel et al. Detection of hypofibrinolysis in stable coronary artery disease using the overall haemostatic potential assay
US7923255B2 (en) Method of detecting platelet thrombosis or organ failure
US9297815B2 (en) Method and kit for detecting condition in patient with disturbance of consciousness
Chandler et al. Elevated hemostatic factor levels as potential risk factors for thrombosis
Margetic Diagnostic algorithm for thrombophilia screening
Lim et al. Global coagulation assays in patients with diabetes mellitus
Colucci et al. Mild hyperhomocysteinemia is associated with increased TAFI levels and reduced plasma fibrinolytic potential
US8088624B2 (en) Method of detecting thrombosis by measuring von Willenbrand factor-cleaving protease
Llobet et al. Platelet hyperaggregability and venous thrombosis risk: results from the RETROVE project
Tsuda et al. Thrombophilia found in patients with moyamoya disease
Rodgers et al. Laboratory and clinical aspects of inherited thrombotic disorders
Andresen et al. The ability of three global plasma assays to recognize thrombophilia
US8101366B2 (en) Assessment of patients with sepsis to determine a requirement for therapeutic intervention with an anti-inflammatory and/or anticoagulatory agent
Rossi et al. Laboratory markers of hypercoagulability
Sivula Disseminated intravascular coagulation in critically ill patients

Legal Events

Date Code Title Description
AS Assignment

Owner name: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ONO, TOMOKO;WATANABE, SHINICHIRO;FURUSAKI, FUMIO;AND OTHERS;REEL/FRAME:021323/0958

Effective date: 20080724

Owner name: MITSUBISHI KAGAKU IATRON, INC., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ONO, TOMOKO;WATANABE, SHINICHIRO;FURUSAKI, FUMIO;AND OTHERS;REEL/FRAME:021323/0958

Effective date: 20080724

AS Assignment

Owner name: MITSUBISHI CHEMICAL MEDIENCE CORPORATION, JAPAN

Free format text: MERGER;ASSIGNOR:MITSUBISHI KAGAKU IATRON, INC.;REEL/FRAME:025414/0427

Effective date: 20090401

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION